No Picture Present
Hildegard M. Schuller
Distinguished Professor
Biomedical and Diagnostic Sciences

Research Interests

Dr. Schuller’s research focuses on the role of neurotransmission in the development and progression of lung cancer and pancreatic cancer and the potential targeting of neurotransmitter receptor pathways for the prevention and therapy of these cancers. Dr. Schuller is the discoverer of a growth-regulating role of nicotinic acetylcholine receptors for small cell lung cancer and of beta-adrenergic receptors and GABA-B receptors for adenocarcinomas of the lungs and pancreas. She was the first to document a direct interaction of cancer causing tobacco-specific nitrosamines with these neurotransmitter receptors and their associated growth-regulating signal transduction pathways. Her pioneering findings have been honored with the Alton Ochsner Award Relating Smoking and Health by the Alton Ochsner Foundation in 1994 and the Distinguished Service Award by the Association for Women veterinarians in 1995. Dr. Schuller has published 228 peer-reviewed articles in national and international professional journals.

Professional Experience

Hildegard M. Schuller, D.V.M., Ph.D. is Chief of the Experimental Oncology Laboratory, Distinguished Professor of Comparative Pathology, College of Veterinary Medicine, University of Tennessee Knoxville, TN, USA. Dr. Schuller earned her professional degrees (D.V.M. and Ph.D. equivalents) at the College of Veterinary Medicine, Giessen (Germany) and the Medical School Hannover (Germany). She held positions as Assistant and Associate Professor at the Medical School Hannover (Germany) followed by appointments at the National Cancer Institute Frederick Cancer research Center, Frederick, MD and the Division of Cancer treatment, national Cancer Institute, Bethesda, MD. Dr. Schuller joined the University of Tennessee in 1985.

Professional Societies

Dr. Schuller is a member of various professional societies, including the American Association for Cancer Research, American Association of Pathology and the Federation of American Societies for Experimental Biology. Dr. Schuller is member of the Editorial Academy of the International Journal of Oncology, and member of the Editorial Board of Anti-Cancer Drugs. She has served on several NIH Study Sections.